Buyer Name: The Royal Marsden NHS Foundation Trust
Buyer Address: Fulham Road, London, UKI33, SW3 6JJ, United Kingdom
Contact Name: Gemma Fahey
Contact Email: gemma.fahey@nhs.net
Buyer Name: The Royal Marsden NHS Foundation Trust
Buyer Address: Fulham Road, London, UKI33, SW3 6JJ, United Kingdom
Contact Name: Gemma Fahey
Contact Email: gemma.fahey@nhs.net
Buyer Name: Central London Community Healthcare NHS Trust
Buyer Address: Ground Floor, 15 Marylebone Road, London, UKI32, NW1 5JD, United Kingdom
The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: • Provision of assay kits and reagents suitable for the intended patient population. • Use of a software platform for analysis and reporting of results. • Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows. • Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components. • Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing. • Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information. • Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required. • MRD sensitivity threshold of 10-5 or lower • Must work on DNA • Performance data must be supported by evidence generated in relevant disease specific Clinical Trials • Recognised technology included in clinical guidelines • Ability to track clonal evolution
No linked documents found for this notice.
Lot 1 Status: complete
Award Title: RMH clonoSEQ® Assay
{
"awards": [
{
"aboveThreshold": true,
"contractPeriod": {
"endDate": "2031-01-19T23:59:59Z",
"startDate": "2026-01-20T00:00:00Z"
},
"date": "2025-12-22T00:00:00Z",
"documents": [
{
"datePublished": "2025-12-30T11:11:50Z",
"description": "Contract award notice on Find a Tender",
"documentType": "awardNotice",
"format": "text/html",
"id": "086403-2025",
"noticeType": "UK6",
"url": "https://www.find-tender.service.gov.uk/Notice/086403-2025"
}
],
"id": "1",
"items": [
{
"additionalClassifications": [
{
"description": "Laboratory reagents",
"id": "33696500",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKI"
}
],
"id": "1",
"relatedLot": "1"
}
],
"mainProcurementCategory": "goods",
"milestones": [
{
"dueDate": "2026-01-15T23:59:59Z",
"id": "1",
"status": "scheduled",
"type": "futureSignatureDate"
}
],
"relatedLots": [
"1"
],
"standstillPeriod": {
"endDate": "2026-01-12T23:59:59+00:00"
},
"status": "pending",
"suppliers": [
{
"id": "GB-PPON-PBYH-2894-GJWD",
"name": "Adaptive Biotechnologies Corporation"
}
],
"title": "RMH clonoSEQ\u00ae Assay",
"value": {
"amount": 1158208.33,
"amountGross": 1389850.0,
"currency": "GBP"
}
}
],
"buyer": {
"id": "GB-PPON-PXLT-9823-WVCY",
"name": "The Royal Marsden NHS Foundation Trust"
},
"date": "2025-12-30T11:11:50Z",
"id": "086403-2025",
"initiationType": "tender",
"language": "en",
"ocid": "ocds-h6vhtk-05fb40",
"parties": [
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "SW3 6JJ",
"region": "UKI33",
"streetAddress": "Fulham Road"
},
"contactPoint": {
"email": "gemma.fahey@nhs.net",
"name": "Gemma Fahey"
},
"details": {
"classifications": [
{
"description": "Public authority - central government",
"id": "publicAuthorityCentralGovernment",
"scheme": "UK_CA_TYPE"
}
],
"url": "https://www.royalmarsden.nhs.uk"
},
"id": "GB-PPON-PXLT-9823-WVCY",
"identifier": {
"id": "PXLT-9823-WVCY",
"scheme": "GB-PPON"
},
"name": "The Royal Marsden NHS Foundation Trust",
"roles": [
"buyer"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "NW1 5JD",
"region": "UKI32",
"streetAddress": "Ground Floor, 15 Marylebone Road"
},
"contactPoint": {
"email": "gemma.fahey@nhs.net",
"name": "Gemma Fahey"
},
"details": {
"url": "https://www.clch.nhs.uk"
},
"id": "GB-PPON-PJXH-4297-MQQW",
"identifier": {
"id": "PJXH-4297-MQQW",
"scheme": "GB-PPON"
},
"name": "Central London Community Healthcare NHS Trust",
"roleDetails": "CLCH host a collaborative, outsourced procurement service - North West London Procurement Services.",
"roles": [
"procuringEntity"
]
},
{
"address": {
"country": "US",
"countryName": "United States",
"locality": "Seattle",
"postalCode": "WA 98109",
"region": "US",
"streetAddress": "1165 Eastlake Ave E, Seattle, United States"
},
"contactPoint": {
"email": "dgalezowski@adaptivebiotech.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"url": "http://www.adaptivebiotech.com",
"vcse": false
},
"id": "GB-PPON-PBYH-2894-GJWD",
"identifier": {
"id": "PBYH-2894-GJWD",
"scheme": "GB-PPON"
},
"name": "Adaptive Biotechnologies Corporation",
"roles": [
"supplier"
]
}
],
"tag": [
"award",
"contract"
],
"tender": {
"description": "The procurement of a next-generation sequencing (NGS)\u2013based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL).\nThe required goods and services include:\n\u2022 Provision of assay kits and reagents suitable for the intended patient population.\n\u2022 Use of a software platform for analysis and reporting of results.\n\u2022 Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows.\n\u2022 Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components.\n\u2022 Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing.\n\u2022 Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information.\n\u2022 Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required.\n\u2022 MRD sensitivity threshold of 10-5 or lower\n\u2022 Must work on DNA\n\u2022 Performance data must be supported by evidence generated in relevant disease specific Clinical Trials\n\u2022 Recognised technology included in clinical guidelines\n\u2022 Ability to track clonal evolution",
"id": "ocds-h6vhtk-05fb40",
"legalBasis": {
"id": "2023/54",
"scheme": "UKPGA",
"uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
},
"lots": [
{
"id": "1",
"status": "complete"
}
],
"procurementMethod": "direct",
"procurementMethodDetails": "Direct award",
"status": "complete",
"title": "RMH clonoSEQ\u00ae Assay"
}
}